Table 2. Chemotherapy regimens for... | American Society of Hematology

Table 2.

Chemotherapy regimens for PCNSL.

Ref	Type	N	Regimen	RT	Result	Other
Abbreviations: PCNSL, primary central nervous system lymphoma; DHAP, dexamethasone, high-dose cytarabine, and cisplatin; PCV, procarbazine, CCNU, and vincristine; MTX, methotrexate; BBBD, blood-brain-barrier disruption; MTV, methotrexate, thiotepa, and vincristine; IT, intrathecal; Ara-C, cytarabine; BOMES, BCNU, vincristine, methotrexate, etoposide, and methylprednisolone; MPV, methotrexate, procarbazine, and vincristine; RT, whole-brain radiotherapy; mo, months; PFS, progression-free survival; pt, patient.
Adapted with permission from Abrey LE, Primary central nervous system lymphoma. The Neurologist. 2000;6:245-254.
35	Series	10	DHAP	+/–	70% response 40% prolonged remission	4 newly diagnosed, 6 recurrent Several did not receive RT
36	Series	10	PCV	+	100% response 30-mo median survival	PCV given post-RT 1 pt received carmustine
11	Series	13	MTX 3.5 g/m²	+	92% response 9+- mo median survival	Survival up to 54+ mos
10	Series	25	MTX 3.5 g/m²	+	88% response 33-mo median survival	59% relapse rate
37	Series	74	MTX BBBD	–	65% complete response 40.7-mo median survival
38	Series	31	MTX 1 g/m²	+	64% response 41-mo median survival
23	Phase II	14	MTV IT Ara-C	–	100% response 16.5-mo median PFS	68.8% alive at 54 mos 2 pts with severe leukoencephalopathy
39	Prospective	19	BOMES	+	84% response rate 6-mo median PFS	5 pts with concurrent systemic lymphoma
40	Series	19	MTX-based 3.5-8 g/m²	–	94% response rate
41	Phase II	102	MPV Ara-C	+	94% response rate 30+-mo median survival
14	Prospective	52	MPV Ara-C	+/–	60-mo median survival	22 older pts did not receive RT

Ref	Type	N	Regimen	RT	Result	Other
Abbreviations: PCNSL, primary central nervous system lymphoma; DHAP, dexamethasone, high-dose cytarabine, and cisplatin; PCV, procarbazine, CCNU, and vincristine; MTX, methotrexate; BBBD, blood-brain-barrier disruption; MTV, methotrexate, thiotepa, and vincristine; IT, intrathecal; Ara-C, cytarabine; BOMES, BCNU, vincristine, methotrexate, etoposide, and methylprednisolone; MPV, methotrexate, procarbazine, and vincristine; RT, whole-brain radiotherapy; mo, months; PFS, progression-free survival; pt, patient.
Adapted with permission from Abrey LE, Primary central nervous system lymphoma. The Neurologist. 2000;6:245-254.
35	Series	10	DHAP	+/–	70% response 40% prolonged remission	4 newly diagnosed, 6 recurrent Several did not receive RT
36	Series	10	PCV	+	100% response 30-mo median survival	PCV given post-RT 1 pt received carmustine
11	Series	13	MTX 3.5 g/m²	+	92% response 9+- mo median survival	Survival up to 54+ mos
10	Series	25	MTX 3.5 g/m²	+	88% response 33-mo median survival	59% relapse rate
37	Series	74	MTX BBBD	–	65% complete response 40.7-mo median survival
38	Series	31	MTX 1 g/m²	+	64% response 41-mo median survival
23	Phase II	14	MTV IT Ara-C	–	100% response 16.5-mo median PFS	68.8% alive at 54 mos 2 pts with severe leukoencephalopathy
39	Prospective	19	BOMES	+	84% response rate 6-mo median PFS	5 pts with concurrent systemic lymphoma
40	Series	19	MTX-based 3.5-8 g/m²	–	94% response rate
41	Phase II	102	MPV Ara-C	+	94% response rate 30+-mo median survival
14	Prospective	52	MPV Ara-C	+/–	60-mo median survival	22 older pts did not receive RT